Rapoport Bernardo L, Theron Annette J, Vorobiof Daniel A, Langenhoven Lizanne, Hall Jacqueline M, Van Eeden Ronwyn I, Smit Teresa, Chan Sze-Wai, Botha Michael C, Raats Johann I, Necker Margriet De, Anderson Ronald
Department of Immunology, Faculty of Health Sciences, University of Pretoria, PO Box 667, Pretoria 0001, South Africa.
The Medical Oncology Centre of Rosebank, 129 Oxford Rd, Corner Northwold Rd, Saxonwold, Johannesburg 2196, South Africa.
Lung Cancer Manag. 2020 Jul 20;9(3):LMT37. doi: 10.2217/lmt-2020-0014.
We investigated the prognostic potential of pretherapy measurement of the neutrophil/lymphocyte ratio (NLR) in patients (n = 56) with non-small-cell lung cancer deemed suitable for treatment with nivolumab.
MATERIALS & METHODS: This was a multicenter, noninterventional, retrospective data analysis, involving five oncology centers.
Patients with prenivolumab NLR values of <5 and ≥5 had respective median overall survival (OS) values of 14.5 and 7.02 months (p = 0.0026). Patients with ≤2 and >2 metastatic sites had median OS values of 11.4 and 6.1 months, respectively (p = 0.0174). A Cox multiple regression model revealed baseline NLR ≥5 as the only variable significantly associated with decreased OS (p < 0.0447).
Pretreatment elevated NLR values are associated with poor outcomes in patients with recurrent metastatic non-small-cell lung cancer treated with nivolumab.
我们研究了中性粒细胞/淋巴细胞比值（NLR）的治疗前测量值对56例被认为适合接受纳武单抗治疗的非小细胞肺癌患者的预后预测潜力。
这是一项多中心、非干预性的回顾性数据分析，涉及五个肿瘤中心。
纳武单抗治疗前NLR值<5和≥5的患者的中位总生存期（OS）分别为14.5个月和7.02个月（p = 0.0026）。转移部位≤2个和>2个的患者的中位OS分别为11.4个月和6.1个月（p = 0.0174）。Cox多元回归模型显示，基线NLR≥5是与OS降低显著相关的唯一变量（p < 0.0447）。
在接受纳武单抗治疗的复发性转移性非小细胞肺癌患者中，治疗前升高的NLR值与不良预后相关。
